At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02157 LEPU BIO-B
Closed Christmas Day 12-24 12:08:29
2.650
+0.000
0.00%
High2.710Low2.580Vol7.53M
Open2.680D1 Closing2.650Amplitude4.91%
Mkt Cap4.53BTradable Cap4.39BTotal Shares1.71B
T/O19.83MT/O Rate0.45%Tradable Shares1.66B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Lepu Biopharma Renews Procurement Contract with Controlling Shareholder
MT Newswires Live  ·  11-27
Lepu Biopharma Renews Procurement Contract with Controlling Shareholder
BUZZ-Lepu Biopharma jumps most in 12 weeks on progress of cancer drug application
Reuters  ·  09-27
BUZZ-Lepu Biopharma jumps most in 12 weeks on progress of cancer drug application
Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%
MT Newswires Live  ·  09-27
Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%
BRIEF-Lepu Biopharma Announces Acceptance Of New Drug Application And Priority- Review Granted By Nmpa To- Mrg003
Reuters  ·  09-27
BRIEF-Lepu Biopharma Announces Acceptance Of New Drug Application And Priority- Review Granted By Nmpa To- Mrg003
Lepu Biopharma Co Ltd - Acceptance of New Drug Application and Priority- Review Granted by Nmpa to- Mrg003
THOMSON REUTERS  ·  09-27
Lepu Biopharma Co Ltd - Acceptance of New Drug Application and Priority- Review Granted by Nmpa to- Mrg003
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Simply Wall St.  ·  08-23
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Lepu Biopharma Records Wider Attributable Loss in H1
MT Newswires Live  ·  08-21
Lepu Biopharma Records Wider Attributable Loss in H1
Lepu Biopharma H1 Revenue RMB 94.8 Million
THOMSON REUTERS  ·  08-21
Lepu Biopharma H1 Revenue RMB 94.8 Million
Lepu Biopharma's Cancer Drug Candidate Receives US FDA's Breakthrough Therapy Designation; Shares Jump 7%
MT Newswires Live  ·  08-05
Lepu Biopharma's Cancer Drug Candidate Receives US FDA's Breakthrough Therapy Designation; Shares Jump 7%
Lepu Biopharma's Cancer Drug Candidate Receives US FDA's Breakthrough Therapy Designation; Shares Jump 7%
MT Newswires Live  ·  08-05
Lepu Biopharma's Cancer Drug Candidate Receives US FDA's Breakthrough Therapy Designation; Shares Jump 7%
BRIEF-Lepu Biopharma Co Says MRG003 Granted Breakthrough Therapy Designation By US FDA
Reuters  ·  08-05
BRIEF-Lepu Biopharma Co Says MRG003 Granted Breakthrough Therapy Designation By US FDA
Lepu Biopharma Co - Mrg003 Granted Breakthrough Therapy Designation by US FDA
THOMSON REUTERS  ·  08-05
Lepu Biopharma Co - Mrg003 Granted Breakthrough Therapy Designation by US FDA
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%
Simply Wall St.  ·  07-19
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Introduction

Company Name.
LEPU BIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.
Issue price:
--